Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2024
PHARMAC looks to fund a medicine to keep bones strong
31 October 2024 - PHARMAC is consulting on a proposal to widen access to denosumab for more people with osteoporosis and ...
Posted by Michael Wonder on 13 Sep 2024
Proposal to fund medicines for lung cancer, breast cancer, and respiratory conditions
13 September 2024 - PHARMAC is seeking feedback on a proposal to fund four new medicines for cancer and respiratory ...
Posted by Michael Wonder on 11 Sep 2024
New medicine and an easier renewal process proposed for people with ADHD
12 September 2024 - PHARMAC is asking for feedback on two changes for people with attention deficit hyperactivity disorder - ...
Posted by Michael Wonder on 21 Aug 2024
PHARMAC proposes to widen access to medicine used in the treatment of heart failure
20 August 2024 - PHARMAC is consulting on plans to widen access to empagliflozin, a medicine used in the treatment ...
Posted by Michael Wonder on 09 Aug 2024
PHARMAC indicates interest in funding cancer treatment bevacizumab
9 August 2024 - PHARMAC is seeking commercial bids from suppliers for the supply of bevacizumab for a range of ...
Posted by Michael Wonder on 19 Jul 2024
PHARMAC proposes to widen access to urinary tract infections treatment and fund a new epilepsy treatment
18 July 2024 - PHARMAC is consulting on improving access to treatment for urinary tract infections, as well as providing ...
Posted by Michael Wonder on 15 Jul 2024
PHARMAC proposal to increase access to five medicines for cancer and other health conditions
12 July 2024 - PHARMAC is looking to increase access to five medicines for a number of cancers, including kidney ...
Posted by Michael Wonder on 06 Jul 2024
Summary of consultation to widen access to cancer medicines and treatments to prevent fungal infections
5 July 2024 - PHARMAC is proposing to widen access to two medicines for cancer and two medicines for prevention ...
Posted by Michael Wonder on 06 Dec 2023
Being more strategic and coordinated when we collaborate
6 December 2023 - Like other health entities, PHARMAC is busy working on strategies to meet the requirements of the ...
Posted by Michael Wonder on 23 Aug 2023
Updates to the Health Technology Assessment Policy and Methods Review including consultation 1 responses published
23 August 2023 - Responses to the first public consultation for the HTA Review (Consultation 1) have now been published ...
Posted by Michael Wonder on 09 Jun 2023
PHARMAC breast cancer cost saving proposal welcome but ignores patients facing “dead-end”
8 June 2023 - Breast Cancer Foundation NZ is urging PHARMAC to widen access to an already funded treatment for ...
Posted by Michael Wonder on 08 Jun 2023
Proposal to widen access to intravenous trastuzumab and change the funded brand
8 June 2023 - The proposal would also give more New Zealanders funded access to intravenous trastuzumab. ...
Posted by Michael Wonder on 29 May 2023
Consultation for various vaccine supply agreements
29 May 2023 - PHARMAC is consulting on potential new supply agreements for multiple vaccines listed in the National Immunisation Schedule. ...
Posted by Michael Wonder on 12 May 2023
Public Consultation: draft 2023-24 Cost Recovery Implementation Statement (CRIS) for listing medicines on the PBS and designated vaccines on the NIP
12 May 2023 - Consultation on the draft 2023-24 Cost Recovery Implementation Statement (CRIS) for listing medicines on the Pharmaceutical ...
Posted by Michael Wonder on 18 Jan 2023
PHARMAC seeking feedback on funding a second spinal muscular atrophy treatment
19 January 2023 - PHARMAC is initiating a consultation today, seeking feedback on a proposal to fund of risdiplam (Evrysdi) for ...